Exact Mass: 323.2056486
Exact Mass Matches: 323.2056486
Found 216 metabolites which its exact mass value is equals to given mass value 323.2056486,
within given mass tolerance error 0.05 dalton. Try search metabolite list with more accurate mass tolerance error
0.01 dalton.
Lysergide
Lysergic acid diethylamide is an ergoline alkaloid arising from formal condensation of lysergic acid with diethylamine. It has a role as a hallucinogen, a serotonergic agonist and a dopamine agonist. It is an ergoline alkaloid, an organic heterotetracyclic compound and a monocarboxylic acid amide. It is functionally related to a lysergamide. D018377 - Neurotransmitter Agents > D018490 - Serotonin Agents > D017366 - Serotonin Receptor Agonists D018377 - Neurotransmitter Agents > D018490 - Serotonin Agents > D012702 - Serotonin Antagonists D002491 - Central Nervous System Agents > D011619 - Psychotropic Drugs > D006213 - Hallucinogens C78272 - Agent Affecting Nervous System > C66885 - Serotonin Antagonist C78272 - Agent Affecting Nervous System > C47794 - Serotonin Agonist
N-Jasmonoylisoleucine
C18H29NO4 (323.20964740000005)
N-Jasmonoylisoleucine belongs to the class of organic compounds known as isoleucine and derivatives. Isoleucine and derivatives are compounds containing isoleucine or a derivative thereof resulting from the reaction of isoleucine at the amino group or the carboxy group, or from the replacement of any hydrogen of glycine by a heteroatom. N-Jasmonoylisoleucine is an extremely weak basic (essentially neutral) compound (based on its pKa). N-Jasmonoylisoleucine is found in pulses. N-Jasmonoylisoleucine is isolated from Pinus mugo (dwarf mountain pine) and Vicia fab.
Alloxydim
L-4-Hydroxyphenylglycyl-L-arginine
C14H21N5O4 (323.15934660000005)
Prodigiosin
A member of the class of tripyrroles that is a red-coloured pigment with antibiotic properties produced by Serratia marcescens. D000890 - Anti-Infective Agents > D000900 - Anti-Bacterial Agents
(2E,8E)-10-hydroxydeca-2,8-dien-4-ynoylcarnitine
(2E,8E)-10-hydroxydeca-2,8-dien-4-ynoylcarnitine is an acylcarnitine. More specifically, it is an (2E,8E)-10-hydroxydeca-2,8-dien-4-ynoic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy. This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. (2E,8E)-10-hydroxydeca-2,8-dien-4-ynoylcarnitine is therefore classified as a medium chain AC. As a medium-chain acylcarnitine (2E,8E)-10-hydroxydeca-2,8-dien-4-ynoylcarnitine is somewhat less abundant than short-chain acylcarnitines. These are formed either through esterification with L-carnitine or through the peroxisomal metabolism of longer chain acylcarnitines (PMID: 30540494). Many medium-chain acylcarnitines can serve as useful markers for inherited disorders of fatty acid metabolism. Carnitine octanoyltransferase (CrOT, EC:2.3.1.137) is responsible for the synthesis of all medium-chain (MCAC, C5-C12) and medium-length branched-chain acylcarnitines in peroxisomes (PMID: 10486279). The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews].
Undeca-2,4,6-trienoylcarnitine
C18H29NO4 (323.20964740000005)
Undeca-2,4,6-trienoylcarnitine is an acylcarnitine. More specifically, it is an undeca-2,4,6-trienoic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy. This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. Undeca-2,4,6-trienoylcarnitine is therefore classified as a medium chain AC. As a medium-chain acylcarnitine Undeca-2,4,6-trienoylcarnitine is somewhat less abundant than short-chain acylcarnitines. These are formed either through esterification with L-carnitine or through the peroxisomal metabolism of longer chain acylcarnitines (PMID: 30540494). Many medium-chain acylcarnitines can serve as useful markers for inherited disorders of fatty acid metabolism. Carnitine octanoyltransferase (CrOT, EC:2.3.1.137) is responsible for the synthesis of all medium-chain (MCAC, C5-C12) and medium-length branched-chain acylcarnitines in peroxisomes (PMID: 10486279). The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews].
Undeca-2,5,8-trienoylcarnitine
C18H29NO4 (323.20964740000005)
Undeca-2,5,8-trienoylcarnitine is an acylcarnitine. More specifically, it is an undeca-2,5,8-trienoic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy. This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. Undeca-2,5,8-trienoylcarnitine is therefore classified as a medium chain AC. As a medium-chain acylcarnitine Undeca-2,5,8-trienoylcarnitine is somewhat less abundant than short-chain acylcarnitines. These are formed either through esterification with L-carnitine or through the peroxisomal metabolism of longer chain acylcarnitines (PMID: 30540494). Many medium-chain acylcarnitines can serve as useful markers for inherited disorders of fatty acid metabolism. Carnitine octanoyltransferase (CrOT, EC:2.3.1.137) is responsible for the synthesis of all medium-chain (MCAC, C5-C12) and medium-length branched-chain acylcarnitines in peroxisomes (PMID: 10486279). The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews].
(4E,6E)-Undeca-4,6,9-trienoylcarnitine
C18H29NO4 (323.20964740000005)
(4E,6E,9E)-Undeca-4,6,9-trienoylcarnitine is an acylcarnitine. More specifically, it is an (4E,6E,9E)-undeca-4,6,9-trienoic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy. This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. (4E,6E,9E)-Undeca-4,6,9-trienoylcarnitine is therefore classified as a medium chain AC. As a medium-chain acylcarnitine (4E,6E,9E)-Undeca-4,6,9-trienoylcarnitine is somewhat less abundant than short-chain acylcarnitines. These are formed either through esterification with L-carnitine or through the peroxisomal metabolism of longer chain acylcarnitines (PMID: 30540494). Many medium-chain acylcarnitines can serve as useful markers for inherited disorders of fatty acid metabolism. Carnitine octanoyltransferase (CrOT, EC:2.3.1.137) is responsible for the synthesis of all medium-chain (MCAC, C5-C12) and medium-length branched-chain acylcarnitines in peroxisomes (PMID: 10486279). The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews].
Undeca-3,5,7-trienoylcarnitine
C18H29NO4 (323.20964740000005)
Undeca-3,5,7-trienoylcarnitine is an acylcarnitine. More specifically, it is an undeca-3,5,7-trienoic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy. This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. Undeca-3,5,7-trienoylcarnitine is therefore classified as a medium chain AC. As a medium-chain acylcarnitine Undeca-3,5,7-trienoylcarnitine is somewhat less abundant than short-chain acylcarnitines. These are formed either through esterification with L-carnitine or through the peroxisomal metabolism of longer chain acylcarnitines (PMID: 30540494). Many medium-chain acylcarnitines can serve as useful markers for inherited disorders of fatty acid metabolism. Carnitine octanoyltransferase (CrOT, EC:2.3.1.137) is responsible for the synthesis of all medium-chain (MCAC, C5-C12) and medium-length branched-chain acylcarnitines in peroxisomes (PMID: 10486279). The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews].
2-(2H-Benzo[d][1,2,3]triazol-2-yl)-4,6-di-tert-butylphenol
Cicloprolol
C18H29NO4 (323.20964740000005)
Lysergide
Prodigiosin
3-Methoxy-2-[(5-methylidene-4-pentylpyrrol-2-ylidene)methyl]-5-(1H-pyrrol-2-yl)-1H-pyrrole
Alanyl-2-(1,1-dimethyl-2-propenyl)dehydrotryptophan anhydride
2-(2H-Benzotriazol-2-yl)-4-(tert-butyl)-6-(sec-butyl)phenol
UV Absorber UV-329
CONFIDENCE standard compound; INTERNAL_ID 722; DATASET 20200303_ENTACT_RP_MIX506; DATA_PROCESSING MERGING RMBmix ver. 0.2.7; DATA_PROCESSING PRESCREENING Shinyscreen ver. 0.8.0; ORIGINAL_ACQUISITION_NO 11720; ORIGINAL_PRECURSOR_SCAN_NO 11715 C1892 - Chemopreventive Agent > C851 - Sunscreen CONFIDENCE standard compound; INTERNAL_ID 722; DATASET 20200303_ENTACT_RP_MIX506; DATA_PROCESSING MERGING RMBmix ver. 0.2.7; DATA_PROCESSING PRESCREENING Shinyscreen ver. 0.8.0; ORIGINAL_ACQUISITION_NO 11762; ORIGINAL_PRECURSOR_SCAN_NO 11757 CONFIDENCE standard compound; INTERNAL_ID 722; DATASET 20200303_ENTACT_RP_MIX506; DATA_PROCESSING MERGING RMBmix ver. 0.2.7; DATA_PROCESSING PRESCREENING Shinyscreen ver. 0.8.0; ORIGINAL_ACQUISITION_NO 11782; ORIGINAL_PRECURSOR_SCAN_NO 11777 CONFIDENCE standard compound; INTERNAL_ID 722; DATASET 20200303_ENTACT_RP_MIX506; DATA_PROCESSING MERGING RMBmix ver. 0.2.7; DATA_PROCESSING PRESCREENING Shinyscreen ver. 0.8.0; ORIGINAL_ACQUISITION_NO 11824; ORIGINAL_PRECURSOR_SCAN_NO 11820 CONFIDENCE standard compound; INTERNAL_ID 722; DATASET 20200303_ENTACT_RP_MIX506; DATA_PROCESSING MERGING RMBmix ver. 0.2.7; DATA_PROCESSING PRESCREENING Shinyscreen ver. 0.8.0; ORIGINAL_ACQUISITION_NO 11837; ORIGINAL_PRECURSOR_SCAN_NO 11833 CONFIDENCE standard compound; INTERNAL_ID 722; DATASET 20200303_ENTACT_RP_MIX506; DATA_PROCESSING MERGING RMBmix ver. 0.2.7; DATA_PROCESSING PRESCREENING Shinyscreen ver. 0.8.0; ORIGINAL_ACQUISITION_NO 11857; ORIGINAL_PRECURSOR_SCAN_NO 11853
2-[6-(diethylamino)purin-9-yl]-5-(hydroxymethyl)oxolane-3,4-diol
C14H21N5O4 (323.15934660000005)
relative retention time with respect to 9-anthracene Carboxylic Acid is 0.710 relative retention time with respect to 9-anthracene Carboxylic Acid is 0.712 relative retention time with respect to 9-anthracene Carboxylic Acid is 0.707 relative retention time with respect to 9-anthracene Carboxylic Acid is 0.708
12xi-hydroxy-14xi-methyl-(13xiH,15xiH)-15,20-dihydro-18,21-dinor-senecionane-11,16-dione|Crotananin|crotananine
(+)-allopumiliotoxin 323B|(7S,8R,8aS,6E)-7,8-Dihydroxy-8-methyl-[(2R,4E,6S)-2,5-dimethyl-6-hydroxy-4-octenylidene]octahydroindolizidine|allopumiliotoxin 323B
3-methoxy-2-[(5-methyl-1-pentylpyrrol-2-yl)methylidene]-4-pyrrol-1-ylpyrrole
4-methoxy-5-(5-methyl-4-pentyl-pyrrol-2-ylmethylene)-1H,5H-[2,2]bipyrrolyl|7-methoxy-1-methyl-2-pentyl-14H,16H-prodigiosene|Prodigiosin
3alpha-(3,4-dihydroxymyrtanoyloxy)tropane|8-methyl-8-azabicyclo[3.2.1]oct-3-yl 3,4-dihydroxy-6,6-dimethylbicyclo[3.1.1]heptan-2-carboxylate|bonabiline A
C18H29NO4 (323.20964740000005)
N-3-oxo-tetradec-7Z-enoyl-L-Homoserine lactone
C18H29NO4 (323.20964740000005)
(S)-2-((S)-3-(1H-Imidazol-4-yl)-2-((S)-pyrrolidine-2-carboxamido)Propanamido)Propanoic acid
C14H21N5O4 (323.15934660000005)
piperidolate
A - Alimentary tract and metabolism > A03 - Drugs for functional gastrointestinal disorders > A03A - Drugs for functional gastrointestinal disorders > A03AA - Synthetic anticholinergics, esters with tertiary amino group C78272 - Agent Affecting Nervous System > C66880 - Anticholinergic Agent > C29704 - Antimuscarinic Agent Piperidolate is an antimuscarinic, inhibits intestinal cramp induced by acetylcholine (rats and dogs).
lsd
CONFIDENCE standard compound; INTERNAL_ID 1625 CONFIDENCE standard compound; EAWAG_UCHEM_ID 3688
(3S,6Z)-3-methyl-6-[[2-(2-methylbut-3-en-2-yl)-1H-indol-3-yl]methylidene]piperazine-2,5-dione
(3S,6Z)-3-methyl-6-[[2-(2-methylbut-3-en-2-yl)-1H-indol-3-yl]methylidene]piperazine-2,5-dione [IIN-based: Match]
(3S,6Z)-3-methyl-6-[[2-(2-methylbut-3-en-2-yl)-1H-indol-3-yl]methylidene]piperazine-2,5-dione [IIN-based on: CCMSLIB00000845126]
(7R,E)-8-((8S,Z)-8-hydroxy-8-methylhexahydroindolizin-6(5H)-ylidene)-4,7-dimethyloct-4-ene-2,3-diol
(7R,8R,E)-6-((2R,E)-6-hydroxy-2,5-dimethyloct-4-en-1-ylidene)-8-methyloctahydroindolizine-7,8-diol
(7R,E)-8-((1S,Z)-1-hydroxyhexahydro-2H-quinolizin-3(4H)-ylidene)-4,7-dimethyloct-4-ene-2,3-diol
N-3-oxo-tetradec-7(Z)-enoyl-L-Homoserine lactone
C18H29NO4 (323.20964740000005)
N-Jasmonoylisoleucine
C18H29NO4 (323.20964740000005)
N-jasmonoyl-isoleucine
C18H29NO4 (323.20964740000005)
1-(Isopropyl(dimethyl)-lambda~5~-azanyl)-3-(1-naphthyloxy)-2-propanol
Procyclidine hydrochloride
C19H30ClNO (323.20158000000004)
D002491 - Central Nervous System Agents > D018726 - Anti-Dyskinesia Agents > D000978 - Antiparkinson Agents D018377 - Neurotransmitter Agents > D018678 - Cholinergic Agents > D018680 - Cholinergic Antagonists C78272 - Agent Affecting Nervous System > C38149 - Antiparkinsonian Agent Procyclidine (Tricyclamol, (±)-Procyclidine) hydrochloride , an anticholinergic agent, is a muscarinic receptor antagonist that also has the properties of an N-methyl-D-aspartate (NMDA) antagonist. Procyclidine hydrochloride can be used in studies of Parkinson's disease and related psychiatric disorders such as Soman-induced epilepsy[1][2].
3-N-BOC-AMINO-1-[2-AMINO-1-(3-FLUORO-PHENYL)-ETHYL]-PYRROLIDINE
3-N-BOC-AMINO-1-[2-AMINO-1-(4-FLUORO-PHENYL)-ETHYL]-PYRROLIDINE
4-(TERT-BUTOXYCARBONYL(4-METHOXYBENZYL)AMINO)BUTANOIC ACID
2-N-BOC-3-(4-METHOXY-PHENYL)-2-METHYLAMINOMETHYL-PROPIONIC ACID
2-N-BOC-3-(3-METHOXY-PHENYL)-2-METHYLAMINOMETHYL-PROPIONIC ACID
METHYL 2-N-BOC-2-AMINOMETHYL-3-(3-METHOXY-PHENYL)-PROPIONATE
Bufetolol
C18H29NO4 (323.20964740000005)
C78272 - Agent Affecting Nervous System > C29747 - Adrenergic Agent > C72900 - Adrenergic Antagonist D018377 - Neurotransmitter Agents > D018663 - Adrenergic Agents > D018674 - Adrenergic Antagonists
Cicloprolol
C18H29NO4 (323.20964740000005)
C78272 - Agent Affecting Nervous System > C29747 - Adrenergic Agent > C72900 - Adrenergic Antagonist
N-(4-(4,4,5,5-Tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)benzamide
C19H22BNO3 (323.16926520000004)
N5-(1-CYCLOHEPTYL-1H-PYRAZOLO[3,4-D]PYRIMIDIN-6-YL)PYRIDINE-2,5-DIAMINE
tert-butyl 4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-2,3,6,7-tetrahydroazepine-1-carboxylate
tert-Butyl (4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)cyclohex-3-en-1-yl)carbamate
5-(PIPERIDINE-1-SULFONYL)-2-PIPERIDIN-1-YL-PHENYLAMINE
Guaiapate
C18H29NO4 (323.20964740000005)
C78273 - Agent Affecting Respiratory System > C66917 - Antitussive Agent
4-(Phenylaminocarbonyl)benzeneboronic acid pinacol ester
C19H22BNO3 (323.16926520000004)
Cinnamaverine
C78272 - Agent Affecting Nervous System > C66880 - Anticholinergic Agent > C29704 - Antimuscarinic Agent
2-[3-(3-hydroxyphenyl)-2,3-dimethylpiperidin-1-yl]-1-phenylethanone
5-(tetrahydro-2H-pyran-4-yloxy)pyridine-3-boronic acid pinacol ester
5-AMINOMETHYL-2-(N,N-DITERT-BUTOXYCARBONYLAMINO)PYRIDINE
(S)-tert-Butyl 2-(benzyloxycarbonylamino)-5-hydroxypentanoate
N,N-bis(trimethylsilyl)aminopropyltrimethoxysilane
3-Amino-3-(hydroxymethyl)-1-(4-octylphenyl)-1,4-butanediol
3-Amino-3-iminopropanoic acid 1-(diphenylmethyl)-3-azetidinyl ester
N-Benzyl-1-(2-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)methanamine
tert-Butyl (2R)-N-(2-(2,2-dimethyl-4H-1,3-benzodioxin-6-yl)-2-hydroxyethyl)carbamate
1H-Imidazole-4-carboxamide, 1-((1R,2S)-2-hydroxy-1-(2-(1-naphthalenyl)ethyl)propyl)-
N-({(1r,2s)-3-Oxo-2-[(2z)-Pent-2-En-1-Yl]cyclopentyl}acetyl)-L-Isoleucine
C18H29NO4 (323.20964740000005)
Cycrimine hydrochloride
C19H30ClNO (323.20158000000004)
C78272 - Agent Affecting Nervous System > C66880 - Anticholinergic Agent > C29704 - Antimuscarinic Agent C78272 - Agent Affecting Nervous System > C38149 - Antiparkinsonian Agent
4-[[Bis(2-hydroxyethyl)amino]methyl]-2,6-ditert-butylphenol
Lysergide-D3; LSD-D3; Lysergic Acid Diethylamide-D3
Ethanaminium, N-[6-(diethylamino)-3H-xanthen-3-ylidene]-N-ethyl-, chloride
(6s)-2-Amino-6-(3-Methoxybiphenyl-3-Yl)-3,6-Dimethyl-5,6-Dihydropyrimidin-4(3h)-One
(2S)-2-amino-1-[(2S)-2-(aminomethyl)pyrrolidin-1-yl]-3-(4-phenylphenyl)propan-1-one
dihydromonacolin L carboxylate
A hydroxy monocarboxylic acid anion that is the conjugate base of dihydromonacolin L acid, obtained by deprotonation of the carboxy group; major species at pH 7.3.
Akuammicine(1+)
C20H23N2O2+ (323.17594379999997)
An ammonium ion that is the conjugate acid of akuammicine, arising from the protonation of the tertiary amino group.
N-[2-[3-oxo-2-(2Z)-2-penten-1-yl-cyclopentyl]acetyl]-L-isoleucine
C18H29NO4 (323.20964740000005)
(2R,3R,4S,5R)-2-(6-aminopurin-9-yl)-5-(2,4-diaminobutyl)oxolane-3,4-diol
4-methyl-2-[[2-[(1R,2R)-3-oxo-2-[(Z)-pent-2-enyl]cyclopentyl]acetyl]amino]pentanoic acid
C18H29NO4 (323.20964740000005)
(2S)-4-methyl-2-[[2-[3-oxo-2-[(Z)-pent-2-enyl]cyclopentyl]acetyl]amino]pentanoic acid
C18H29NO4 (323.20964740000005)
(2E,4E,7R)-11-[(2R,3R)-3-(hydroxymethyl)-4-oxooxetan-2-yl]-3,5,7-trimethylundeca-2,4-dienoate
(4E,6E)-Undeca-4,6,9-trienoylcarnitine
C18H29NO4 (323.20964740000005)
3-Methoxy-2-[(5-methylidene-4-pentylpyrrol-2-ylidene)methyl]-5-(1H-pyrrol-2-yl)-1H-pyrrole
1-[3-[(8-methyl-5H-pyrimido[5,4-b]indol-4-yl)amino]propyl]-2-pyrrolidinone
1-[2-(3,4-dihydro-1H-isoquinolin-2-yl)ethyl]-3-(4-ethylphenyl)urea
2-[(Dimethylamino)methyl]-4-spiro[1,6-dihydrobenzo[h]quinazoline-5,1-cyclohexane]one
N-[4-[(cyclohexylamino)-oxomethyl]phenyl]-3-pyridinecarboxamide
N,N-diethyl-4-[oxo-(2,4,6-trimethylphenyl)methyl]benzamide
1-[4-[4-[(4-Methylphenyl)methylamino]phenyl]-1-piperazinyl]ethanone
1-[4-[4-[(3-Methylphenyl)methylamino]phenyl]-1-piperazinyl]ethanone
3,4-dimethyl-N-[4-(4-methyl-1-piperazinyl)phenyl]benzamide
2,2,7,7,9,9-hexamethyl-10-oxido-8H-pyrano[2,3-b]carbazol-10-ium
N-({(1R)-3-oxo-2-[(2Z)-pent-2-en-1-yl]cyclopentyl}acetyl)-L-isoleucine
C18H29NO4 (323.20964740000005)
5,5-dimethyl-2-[(5-methyl-4-phenyl-1H-pyrazol-3-yl)iminomethyl]cyclohexane-1,3-dione
(1S,12S,14R,15E)-15-ethylidene-17-methyl-3-aza-17-azoniapentacyclo[12.3.1.02,10.04,9.012,17]octadeca-2(10),4,6,8-tetraene-13-carboxylic acid
C20H23N2O2+ (323.17594379999997)
N-[(4E,8E,12E)-1,3-dihydroxyheptadeca-4,8,12-trien-2-yl]acetamide
N-[(4E,8E,12E)-1,3-dihydroxyhexadeca-4,8,12-trien-2-yl]propanamide
N-[(4E,8E,12E)-1,3-dihydroxypentadeca-4,8,12-trien-2-yl]butanamide
N-[(4E,8E,12E)-1,3-dihydroxytetradeca-4,8,12-trien-2-yl]pentanamide
2-Deamino-2-hydroxyneamine
An amino cyclitol glycoside that is 2-deoxystreptamine in which the pro-R hydroxy group is substituted by a 6-amino-6-deoxy-alpha-D-glucosyl residue.
methyl 2,2-dimethyl-4,6-dioxo-5-[(E)-N-prop-2-enoxy-C-propylcarbonimidoyl]cyclohexane-1-carboxylate
N-[(+)-7-isojasmonyl]-L-isoleucine
C18H29NO4 (323.20964740000005)
An L-isoleucine derivative resulting from the formal condensation of the carboxy group of (+)-7-isojasmonic acid with the amino group of L-isoleucine.
Lysergic acid diethylamide
An ergoline alkaloid arising from formal condensation of lysergic acid with diethylamine.
S3QEL-2
S3QEL-2, a suppressor of superoxide production from mitochondrial complex III, potently and selectively suppresses site IIIQo superoxide production (IC50=1.7 μM). S3QEL-2 does not affect oxidative phosphorylation, and normal electron flux. S3QEL-2 inhibits HIF-1α accumulation[1].
(3r,5s,7ar,11as)-3-(chloromethyl)-5-hexyl-1h,2h,3h,5h,6h,7h,7ah,11h-pyrrolo[2,1-j]quinolin-10-one
C19H30ClNO (323.20158000000004)
(1s,5r)-1-(butanoyloxy)-6,8-dimethyl-8-azabicyclo[3.2.1]octan-3-yl (2e)-2-methylbut-2-enoate
C18H29NO4 (323.20964740000005)
8-(8-hydroxy-8-methyl-hexahydroindolizin-6-ylidene)-4,7-dimethyloct-4-ene-2,3-diol
(3s,6z)-3-methyl-6-{[2-(2-methylbut-3-en-2-yl)-1h-indol-3-yl]methylidene}-3h-pyrazine-2,5-diol
(2s,3r)-2-({1-hydroxy-2-[(1r,2s)-3-oxo-2-[(2z)-pent-2-en-1-yl]cyclopentyl]ethylidene}amino)-3-methylpentanoic acid
C18H29NO4 (323.20964740000005)
n-(1,3-dihydroxy-3-methyl-4-oxopentan-2-yl)-6,8-dimethyldeca-2,4,6-trienamide
C18H29NO4 (323.20964740000005)
7-hydroxy-4,5,6-trimethyl-2,9-dioxa-14-azatricyclo[9.5.1.0¹⁴,¹⁷]heptadec-11-ene-3,8-dione
5-hydroxy-6-methyl-3-{[2-(2-methylbut-3-en-2-yl)-1h-indol-3-yl]methylidene}-1,6-dihydropyrazin-2-one
methyl 1-[(dimethylamino)methyl]-3a-hydroxy-5-isopropyl-7a-methyl-7-oxo-1,2,3,4-tetrahydroindene-4-carboxylate
C18H29NO4 (323.20964740000005)
2-({1-hydroxy-2-[3-oxo-2-(pent-2-en-1-yl)cyclopentyl]ethylidene}amino)-3-methylpentanoic acid
C18H29NO4 (323.20964740000005)